Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review outlines the current regulatory framework for cosmetics under the FD&C Act, highlighting that they are less strictly regulated than drugs, but notes potential future changes due to proposed legislations requiring stronger safety measures.

This study highlights that topical ruxolitinib cream is FDA-approved for mild to moderate atopic dermatitis and nonsegmental vitiligo in patients aged 12 and older, but its use in other skin conditions like frontal fibrosing alopecia remains under-researched and needs further exploration in clinical practice.

This article reflects on the history and significance of the FDA's approval of topical minoxidil for treating androgenetic alopecia in men and women, dating back to 1988 and 1991 respectively.

This abstract reports that topical minoxidil is currently the only FDA-approved treatment for pattern hair loss in both men and women.

This retrospective review found that platelet-rich plasma products from FDA-cleared devices for alopecia were inconsistent, highlighting a need for more detailed examination of preparation methods.

This narrative review reflects on the challenges faced by FDA's Oncologic Drugs Advisory Committee members, highlighting public pressure, decision-making complexity, and the evolving landscape of cancer drug development.

This study revealed significant signals of drug-related cognitive disorders in several medications that lack relevant FDA label warnings, suggesting a need for increased clinical awareness and potential label updates.

In this review, researchers discuss 50 novel drugs approved by the FDA in 2024, highlighting key agents like vadadustat for anemia in chronic kidney disease and donanemab for Alzheimer’s, and focusing on their roles in pharmacy education and clinical decision-making.

This study analyzed adverse event reports from the FDA database and found that drugs such as immunomodulatory agents, monoclonal antibodies, minoxidil, contraceptives, and anti-TNF drugs are frequently associated with hair loss, suggesting guidance for dermatologists in identifying common medications linked to alopecia.

This article reviews the decade since finasteride's FDA approval, noting hair restoration surgeons' experience with the drug but reports no new study results.

This study found that the current approval processes by major regulators like the EMA and FDA for HPV vaccines may rely on only half of the available trial data.

This review discusses advancements in the genetic understanding of androgenic alopecia and the FDA-approved treatments, including a new laser hair comb, but reports no clinical results.

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

This review examines the incidence and management of dermatologic adverse effects from FDA-approved oral targeted cancer therapies, highlighting frequent occurrences like rashes and rarer severe conditions such as Stevens-Johnson Syndrome.

This review found that hormonal therapies, including FDA-approved combined oral contraceptive pills and spironolactone, are effective and well-tolerated treatments for acne vulgaris in adolescents with or without endocrine disorders, providing alternative options to antibiotics.

This study reported that dupilumab, an FDA-approved biologic, is a safe and effective first-line systemic treatment for children with moderate-to-severe atopic dermatitis, showing sustained skin improvement and itch reduction, with injection site reactions and conjunctivitis as potential side effects.

In this study, researchers analyzed adverse events linked to avacopan using FDA data, finding no high-priority safety concerns but identifying five potential new adverse events, including alopecia, primarily among American patients, and noting a higher risk of liver dysfunction in Japanese patients.

New treatments for vitiligo, including the first FDA-approved option, are improving patient care and quality of life.

This abstract discusses finasteride and dutasteride's mechanisms in treating androgenetic alopecia and notes FDA approval for finasteride, but reports no new clinical results.

This study found that among ten identified medications associated with ejaculatory disorders, Paroxetine and Tamsulosin were mainly linked to delayed and retrograde ejaculation, while Finasteride and Sildenafil were most associated with painful ejaculation and ejaculation failure according to reports from FDA-FAERS and Eudra-Vigilance databases.

This article reviews the history and methods of hair removal, highlighting electrolysis as the only FDA-recognized permanent option, but it presents no new findings.

This study reviewed treatments for chemotherapy-induced hair loss, finding that scalp cooling is FDA-approved for prevention, while minoxidil and bimatoprost may aid post-chemotherapy regrowth. The authors emphasized tailored therapies and the potential utility of tools like trichoscopy and trichogram.

This article discusses the challenges in treating hidradenitis suppurativa, highlighting that adalimumab is currently the only FDA-approved treatment, and reports no clinical results.

In this in-vitro study, researchers identified finasteride as the most effective FDA-approved drug for expanding functional myeloid-derived suppressor cells, suggesting its potential future use in immunosuppressive therapies.

This article discusses alopecia areata, highlighting its autoimmune nature and the lack of FDA-approved treatments, without providing new research findings.

This editorial discusses the rationale and limited evidence for "medical marijuana," suggesting that THC, an FDA-approved alternative, may often be a more appropriate choice for clinical use.

The authors concluded that pattern hair loss is a complex condition with limited treatment efficacy and two FDA-approved drugs, finasteride and minoxidil, to slow its progression.

This study reviewed various lipolytic agents for reducing submental fat and highlighted that while deoxycholic acid is FDA-approved, other compounds like phosphatidylcholine with deoxycholate lack cosmetic approval due to safety concerns. Understanding these agents' mechanisms and anatomy is crucial for safe fat reduction applications.

In this study, researchers used computational modeling and virtual screening to identify two FDA-approved drugs, Tadalafil and Finasteride, that may effectively inhibit key proteins involved in melanoma progression, suggesting potential for new therapeutic strategies against aggressive melanoma.

This review highlights various alternative and complementary treatments for androgenic alopecia, noting that while only two FDA-approved options exist, increased awareness among dermatologists of supportive evidence for other therapies may better inform patient education.